1. Biological response modifiers --; 2. Antitumor effects of interferons --; 3. Transcatheter management of neoplasms --; 4. Antifolates --; 5. Purine antimetabolites --; 6. Alkylating agents --; 7. Platinum compounds --; 8. Nitrosoureas --; 9. Triazine and hydrazine derivatives --; 10. Anthracycline antibiotics --; 11. Actinomycin --; 12. Other antitumor antibiotics --; 13. Plant alkaloids: the vinca alkaloids --; 14. Non-alkaloid natural products as anticancer agents --; 15. Hyperthermia --; 16. Current advances in bone marrow transplantation for cancer treatment --; 17. Hematologic support of the patient with malignancy --; 18. The sphygmochron for chronobiologie blood pressure and heart rate assessment in cancer patients --; 19. Nutritional support of cancer patients during cancer progression --; 20. Palliative chemotherapy: Cancer chemotherapy-induced nausea and vomiting --; 21. Chronic pain management --; 22. Care for the terminally ill: Death and dying --; Index of subjects.
This volume, the last in this series on cancer growth and Moreover, the current status of plant-derived vinca alkaƯ progression, is a companion volume to Volume IX and loids and non-alkaloid natural products is summarized. further explores established and novel approaches for the Advances in hyperthermia and additional approaches for therapy of patients with malignant neoplasms. The straƯ the therapy of malignancies are also presented. tegies reflected in these volumes are direct extrapolations The volume continues with chapters on bone marrow from the basic science of cancer biology, growth and proƯ transplantation as well as hematologic and nutritional supƯ gression described in earlier volumes of this series. Some port for the cancer patient. Blood pressure in the cancer approaches are directed towards the eradication or modifiƯ patient, therapy for nausea and vomiting as well as pain are cation of the properties of heterogeneous malignant tumor discussed. The last chapter is devoted to the problems of the cells at various stages of tumor progression, while other terminally ill, including evaluations of the burden relatives approaches are directed towards modification of the host and friends of the cancer patient have to bear. antitumor defense systems, e. g., enhancement of host antiƯ It is clear that important advances in the basic science of tumor immune reactivity.